Is AbbVie Stock a Buy Now?
Pharmaceutical giant (NYSE: ABBV) is getting used to life without Humira. Not literally, but the former global top-seller did lose patent exclusivity last year, and sales plummeted as cheaper generic alternatives entered the market.
So, why has AbbVie stock soared nearly 30% over the past three months to new all-time highs? More importantly, have investors missed their opportunity to buy the stock and still see satisfactory investment returns?
AbbVie's management has put on a masterclass in executing its transition away from a patent-protected Humira, and it makes the stock a compelling long-term investment idea.
Source Fool.com
AbbVie Inc. Stock
€148.14
2.510%
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
As a result the target price of 175 € shows a slightly positive potential of 18.13% compared to the current price of 148.14 € for AbbVie Inc..
